Emodin inhibits HMGB1-induced tumor angiogenesis in human osteosarcoma by regulating SIRT1

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Emodin exhibits anti-cancer properties, including anti-angiogenesis, but its precise mechanisms remain unclear.
• Osteosarcoma (OS) angiogenesis is a critical factor in tumor progression and metastasis.
• Understanding emodin's molecular targets is crucial for developing novel anti-cancer therapies.

Purpose of the Study:

• To investigate the anti-angiogenesis mechanisms of emodin in human osteosarcoma.
• To elucidate the role of SIRT1 in emodin's anti-angiogenic effects.
• To assess the impact of emodin on SIRT1 expression and activity in OS.

Main Methods:

• In vivo and in vitro models of human osteosarcoma xenografts.
• Immunofluorescence assay for von Willebrand Factor (vWF) expression.
• MTT assay to determine non-proliferative inhibitory concentrations of emodin.
• siRNA technique to silence SIRT1 expression.
• Real-time PCR and Western blotting to analyze SIRT1, VEGF, and H4-k16Ac expression.

Main Results:

• Emodin administration significantly attenuated angiogenesis in both OS and HMGB1-treated OS models.
• Emodin treatment markedly enhanced SIRT1 expression level and deacetylation activity.
• SIRT1 silencing exacerbated HMGB1-induced angiogenesis and impaired emodin's anti-angiogenic effect.

Conclusions:

• Emodin exerts anti-angiogenesis effects in human osteosarcoma.
• The anti-angiogenic mechanism of emodin involves the elevation of SIRT1 expression and deacetylation activity.
• SIRT1 plays a critical role in mediating emodin's anti-angiogenesis effects in OS.